ZURA SEC filings, in plain English
Everything JATT Acquisition Corp has filed with the SEC that we hold — 40 filings, newest first, 7 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Exhibit 99.1 to an 8-K filed under JATT Acquisition Corp's CIK by Zura Bio: an August 2026 corporate overview presentation. It describes tibulizumab as a bispecific antibody inhibiting IL-17 and BAFF, with three programs — hidradenitis suppurativa, systemic sclerosis and polymyalgia rheumatica. The deck states topline data expected from the HS and SSc Phase 2 studies in Q4 2026 and H1 2027 respectively, and a cash runway through at least year end 2028. The disclaimer states Zura Bio has not completed any clinical trials and has no products approved for commercial sale. Why it matters: The two dated readouts and the stated runway are the company's own expectations in an investor deck, not filed financial statements. The presentation is the source for the pipeline timing; the numbers behind the runway are not given in it.
What changed: Zura Bio reported Q2 2026 results: cash of $205.1M as of June 30, 2026 (up from $109.4M at YE 2025), with enrollment complete in both Phase 2 tibulizumab studies (TibuSHIELD: 247 participants; TibuSURE: 91 participants) and a third indication (PMR) planned by year-end 2026. R&D expenses rose to $20.7M from $8.7M YoY, with a net loss of $26.3M ($0.21/share). Why it matters: The company has sufficient cash to fund operations through at least end of 2028, with key clinical catalysts upcoming: TibuSHIELD topline data expected Q4 2026 and TibuSURE data expected H1 2027. Share count increased to 95.4M Class A shares outstanding from 73.7M at YE 2025, reflecting significant equity issuance.
What changed: The 10-Q filed under Commission file number 001-40598 is that of Zura Bio Limited (Nasdaq: ZURA) for the quarter ended June 30, 2026, with 95,829,137 Class A ordinary shares outstanding as of August 11, 2026. Why it matters: A company with 95.8 million shares outstanding states on its own cover pages that it has completed no clinical trials and has nothing approved — the entire value proposition is future financing and future data. The condensed consolidated financial statements are not in the portion read here.
What changed: Zura Bio Ltd. (Nasdaq: ZURA), the JATT Acquisition Corp successor, furnished a corporate overview presentation dated July 2026. The captured text is the forward-looking statements disclaimer, identifying the topics the deck addresses: clinical development plans, the design, conduct, enrolment and timing of trials, expected milestones and data readouts, the safety, efficacy and commercial potential of product candidates, market opportunities, and cash resources and projected runway. Why it matters: The disclaimer inventory is itself informative for a clinical-stage de-SPAC: the deck addresses projected cash runway alongside trial timing, which are the two variables that determine whether former ZURA holders face a financing before the next readout. The substantive figures are in the slides rather than the captured text, so this summary cannot state the runway or the milestone dates — confidence is reduced accordingly and the exhibit itself should be consulted.
What changed: Items 5.02 and 5.07: at Zura Bio Limited's June 17, 2026 annual general meeting, held with a quorum present, shareholders approved an amendment and restatement of the company's 2023 Equity Incentive Plan, which the board had approved on April 23, 2026 subject to shareholder approval and which became effective immediately on approval. Shareholders also voted on four proposals in total, including the election of eight directors and the ratification of WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026. Why it matters: The amended equity plan is the item with economic consequence: expanding an incentive plan authorises additional share issuance, which dilutes public shareholders who came in through the SPAC. The material terms are not restated in the 8-K itself and are incorporated from the April 30, 2026 proxy statement, so the size of the increase has to be read there. The rest of the meeting, an eight-director slate and auditor ratification, is routine.
What changed: Zura Bio Limited filed as definitive additional materials a Form 8-K reporting under Item 5.02 that on May 20, 2026 Someit Sidhu notified the company of his decision to resign from its board of directors, effective as of May 21, 2026. The company states that the resignation is not due to any disagreement with it on any matter relating to its operations, policies or practices. The report is dated May 22, 2026 and signed by Kim Davis, Chief Operating Officer, Chief Legal Officer and Corporate Secretary. Why it matters: Filing a director resignation as proxy material, rather than only as a current report, puts it in front of holders while a solicitation is live — that is what the DEFA14A wrapper is doing here. The filing itself carries no meeting date, no record date, no proposal and no vote threshold, and it names no successor or replacement nominee, so the composition of the board a holder is voting on must be read from the proxy statement as adjusted by this departure. Nothing in it bears on trust, redemption or a business-combination deadline.
What changed: Zura Bio Limited, the Cayman successor to JATT Acquisition Corp, called a virtual annual general meeting for Wednesday, June 17, 2026 at 12:00 p.m. ET, record date Monday, April 20, 2026, using Full Set Delivery of paper proxy materials. There were 94,880,710 Class A ordinary shares issued and outstanding on the record date, and quorum requires holders of at least a majority of those shares. Holders vote to elect directors, to ratify WithumSmith+Brown, PC for the fiscal year ended December 31, 2026, and to approve an amended and restated 2023 equity plan. Why it matters: The amended 2023 Plan is written so its share reserve grows in proportion to total economic capitalization, which means the equity pool expands automatically as the company issues stock - dilution that compounds with any future raise rather than requiring a fresh shareholder vote. Against 94.9 million Class A shares at a $5.37 reference price, that is the main structural item on the ballot; no trust or redemption right survives from the JATT SPAC.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“● Our recurring losses from operations and financial condition could raise substantial doubt about our ability to continue as a going concern. ● If we are unable to raise capital when needed, or on acceptable terms, we may be forced”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.